A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both ...

A McGill University study of more than 450,000 patients found that incretin-based Type 2 diabetes drugs, including GLP-1 ...

Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use. (HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

Investigators compared sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4is) in a propensity-score matched group of patients with gout and type 2 diabetes.

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

"I think these are very interesting findings, even if the study wasn't powered for cardiovascular end points," said lead investigator Dr Baptist Gallwitz (Eberhard-Karls-University Tübingen, Germany).